在人工胰腺系统中对普拉姆林提德剂量算法的in silico评估
Borja Pons Torres1, Iván Sala-Mira2, Clara Furió-Novejarque3
1Instituto Universitario de Investigación Concertado de Ingeniería Mecánica y Biomecánica, Universitat Politècnica de València, València, Spain.
Computers in biology and medicine
|June 13, 2025
概括
将pramlintide添加到人造胰腺系统可以改善1型糖尿病 (T1DM) 管理范围的时间. 这项研究模拟了胰岛素加上普拉姆林提德的策略,显示出显著的血糖控制增强.
科学领域:
- 生物医学工程 生物医学工程
- 内分泌学 在内分泌学.
- 计算生物学 计算生物学
背景情况:
- 普拉姆林提德延迟胃空气,使其成为人工胰腺 (AP) 系统中胰岛素的潜在辅助剂.
- 普拉姆林提德模拟模型的有限可用性阻碍了对1型糖尿病 (T1DM) 联合疗法的测试.
研究的目的:
- 在T1DM UVA/帕多瓦模拟器中集成pramlintide药理动力学/药理动力学模型.
- 为AP系统调整和验证四种胰岛素加普拉姆林提德控制算法.
- 为了评估与单独胰岛素控制器相比,增强了pramlintide的AP策略的性能.
主要方法:
- 将最近的普拉姆林PK/PD模型纳入T1DM UVA/帕多瓦模拟器.
- 开发和调整四种控制算法:仅用胰岛素和胰岛素加上普拉姆林提德 (基于玻尿酸或比率).
- 对模拟的血糖控制指标进行比较分析,重点关注范围内的时间.
主要成果:
- 与单独胰岛素策略相比,胰岛素加普拉姆林提德算法显示范围的时间有所改善 (3.00%10.53%).
- 模拟结果与现有临床试验的发现保持一致.
- 该研究成功地在AP模拟器中验证了pramlintide模型.
结论:
- 模拟的胰岛素加上普拉姆林提德策略在T1DM管理中提供了增强的血糖控制.
- 开发的模拟框架促进了新AP控制算法的测试.
- 未来的研究应该专注于患者特定的模型个性化和在不同的条件下进行测试.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
161
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
161
Glucagon-like Receptor Agonists
308
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
308
Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Insulin: Biosynthesis, Chemistry, and Preparation
365
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
365


